VIVUS announced the appointment of Ken Suh to the position of president.  Previously, Mr. Suh was president and chief executive officer of Willow Biopharma Inc., a wholly-owned subsidiary of VIVUS, Inc. As president of VIVUS, Mr. Suh will work to advance the Company toward its core objectives of product portfolio optimization and enterprise value creation. 
 
Mr. Suh founded Willow Biopharma in 2015, and in April 2018, Willow Biopharma became a wholly-owned subsidiary of VIVUS. Prior to establishing Willow, he founded KRIM Biopharma Inc., where he served as president, chief executive officer and director. 

“Ken has been instrumental in developing and executing our corporate strategy since joining VIVUS in April, and his appointment as President reflects the important contributions he has already made toward advancing our key business objectives, most notably, the recent acquisition of PANCREAZE,” said John Amos, chief executive officer at VIVUS. “Ken has a critical role to play in helping us build a sustainable and profitable specialty pharmaceutical company that creates value for patients and investors.”